Literature DB >> 12665690

Expression and characterization of biologically active human Fas ligand produced in CHO cells.

Sabrina Zappitelli1, Laura D'Alatri, Allesandra Ciucci, Giuseppe Raucci, Angela Faiella, Meri Gabrielli, Massimo Parlani, Alessandro Bressan, Carlo A Maggi, Cristina Goso, Luigi Rotondaro.   

Abstract

We describe an expression system for high-yield production of recombinant soluble human FasL (rsh- FasL) in CHO cells. After one round of selection for gene amplification, cell lines producing rsh-FasL up to 60 microg/L x 10(6) cells in 24 h were obtained. Cell lines were grown in protein-free medium as suspension cultures. The protein secreted into growth medium was purified by immunoaffinity. The rsh-FasL thus obtained was further fractionated by gel filtration and a form of approx 140 kDa was isolated and characterized. Mass spectral analysis yielded a main peak of 28,321.15 Da, while, although to a lesser extent, dimeric and trimeric forms were also detected according to the described oligomerized state of native FasL. Our procedure permits consistent production of biologically active rsh-FasL as shown in tests on FasL-sensitive cells and in in vitro binding assays.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12665690     DOI: 10.1385/MB:23:3:189

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  20 in total

1.  Characterization of Fas (Apo-1, CD95)-Fas ligand interaction.

Authors:  P Schneider; J L Bodmer; N Holler; C Mattmann; P Scuderi; A Terskikh; M C Peitsch; J Tschopp
Journal:  J Biol Chem       Date:  1997-07-25       Impact factor: 5.157

Review 2.  Environmental effects on protein glycosylation.

Authors:  C F Goochee; T Monica
Journal:  Biotechnology (N Y)       Date:  1990-05

3.  Expression of biologically active mouse and human CD95/APO-1/Fas ligand in the baculovirus system.

Authors:  S M Mariani; B Matiba; T Sparna; P H Krammer
Journal:  J Immunol Methods       Date:  1996-06-14       Impact factor: 2.303

4.  Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.

Authors:  T Suda; T Takahashi; P Golstein; S Nagata
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

5.  A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity.

Authors:  K Ichikawa; H Yoshida-Kato; M Ohtsuki; J Ohsumi; J Yamaguchi; S Takahashi; Y Tani; M Watanabe; A Shiraishi; K Nishioka; S Yonehara; N Serizawa
Journal:  Int Immunol       Date:  2000-04       Impact factor: 4.823

6.  In vivo inhibition of Fas ligand-mediated killing by TR6, a Fas ligand decoy receptor.

Authors:  K Connolly; Y H Cho; R Duan; J Fikes; T Gregorio; D W LaFleur; Z Okoye; T W Salcedo; G Santiago; S Ullrich; P Wei; K Windle; E Wong; X T Yao; Y Q Zhang; G Zheng; P A Moore
Journal:  J Pharmacol Exp Ther       Date:  2001-07       Impact factor: 4.030

7.  High-level expression of a cDNA for human granulocyte colony-stimulating factor in Chinese hamster ovary cells. Effect of 3'-noncoding sequences.

Authors:  L Rotondaro; L Mazzanti; A Mele; G Rovera
Journal:  Mol Biotechnol       Date:  1997-06       Impact factor: 2.695

8.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves.

Authors:  A DeLean; P J Munson; D Rodbard
Journal:  Am J Physiol       Date:  1978-08

Review 9.  The Fas death factor.

Authors:  S Nagata; P Golstein
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

10.  Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity.

Authors:  P Schneider; N Holler; J L Bodmer; M Hahne; K Frei; A Fontana; J Tschopp
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.